Kingchem (Liaoning) Life Science Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Kingchem (Liaoning) Life Science has been growing earnings at an average annual rate of 11.3%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 8.3% per year. Kingchem (Liaoning) Life Science's return on equity is 3.1%, and it has net margins of 11.7%.
Belangrijke informatie
11.3%
Groei van de winst
4.8%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 10.9% |
| Inkomstengroei | 8.3% |
| Rendement op eigen vermogen | 3.1% |
| Nettomarge | 11.7% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Kingchem (Liaoning) Life Science geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 568 | 67 | 110 | 35 |
| 30 Jun 24 | 597 | 94 | 117 | 33 |
| 31 Mar 24 | 677 | 150 | 117 | 29 |
| 31 Dec 23 | 767 | 174 | 118 | 30 |
| 30 Sep 23 | 736 | 153 | 126 | 29 |
| 30 Jun 23 | 774 | 173 | 115 | 28 |
| 31 Mar 23 | 743 | 152 | 106 | 28 |
| 01 Jan 23 | 717 | 161 | 105 | 26 |
| 30 Sep 22 | 714 | 179 | 107 | 23 |
| 30 Jun 22 | 670 | 148 | 104 | 25 |
| 31 Mar 22 | 609 | 116 | 97 | 25 |
| 31 Dec 21 | 549 | 85 | 90 | 25 |
| 31 Dec 20 | 464 | 59 | 77 | 21 |
| 31 Dec 19 | 415 | 58 | 69 | 17 |
| 31 Dec 18 | 301 | 27 | 58 | 13 |
Kwaliteitswinsten: 301509 has high quality earnings.
Groeiende winstmarge: 301509's current net profit margins (11.7%) are lower than last year (20.7%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 301509's earnings have grown by 11.3% per year over the past 5 years.
Versnelling van de groei: 301509's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 301509 had negative earnings growth (-56.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).
Rendement op eigen vermogen
Hoge ROE: 301509's Return on Equity (3.1%) is considered low.